The PARTNER 3 - AVIV Trial


About this study

To assess the safety and effectiveness of the SAPIEN 3 (Edwards Lifesciences, Irvine, California) transcatheter heart valve in patients with a failing aortic bioprosthetic valve.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

  • Failing surgical or transcatheter bioprosthetic valve in the aortic position demonstrating ≥ moderate stenosis and/or ≥ moderate insufficiency.
  • Bioprosthetic valve with an internal orifice diameter of 16 mm to 27 mm.
  • NYHA Functional Class ≥ II.
  • Heart Team agrees valve implantation will likely benefit the patient.
  • The study patient has been informed of the nature of the study, agrees to its provisions and has provided written informed consent as approved by the Institutional Review Board (IRB) of the respective clinical site.
  • Patients with mild or trace paravalvular regurgitation.

Exclusion Criteria:

  • Surgical or transcatheter valve in the mitral position (mitral rings are not an exclusion).
  • Severe regurgitation (> 3+) or stenosis of any other valve.
  • With the exception of patients with mild or trace paravalvular regurgitation (who may particiate in this study), failing valve has paravalvular regurgitation (includes those instances that have been previously treated with a plug due to paravalvular regurgitation). 
  • Failing valve is unstable, rocking, or not structurally intact.
  • Increased risk of coronary obstruction by prosthetic leaflets of the failing valve.
  • Increased risk of embolization of THV (e.g., surgical valve that is non-stented and non-calcified).
  • Known bioprosthetic valve with residual mean gradient >20 mmHg at the end of the index procedure for implantation of the original valve.

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status Contact

Rochester, Minn.

Mayo Clinic principal investigator

David Holmes, M.D.

Closed for enrollment

Contact information:

Structural Heart Disease Research Coordinators

(507) 255-6133

More information


Publications are currently not available

Mayo Clinic Footer